The absence expression of estrogen and progesterone receptors (ER\PR) as well as human epidermal growth factor receptor 2 (HER-2) defines triple-negative breast cancer (TNBC) in molecular perspective, which narrows down receptor targeted therapeutic choices and leads to its unfavorable prognosis (1–3). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.